Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 3/20 | 1.00 |
| ▸ | CES2 | O00748 | 1/20 | 0.71 |
| ▸ | CES1 | P23141 | 1/20 | 0.71 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.67 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.67 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.67 |
| ▸ | STS | P08842 | 2/20 | 0.63 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.62 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.62 |
| ▸ | TNKS | O95271 | 1/20 | 0.62 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.62 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.62 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.62 |
| ▸ | NPC1 | O15118 | 5/20 | 0.59 |
| ▸ | RAB9A | P51151 | 4/20 | 0.59 |
| ▸ | CA1 | P00915 | 1/20 | 0.59 |
| ▸ | CA2 | P00918 | 1/20 | 0.59 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29503138 | 1.00 | PARP1 (1.00) | PARP1CES2CES1PRSS1PRSS2 | |
| Hydrochloric Acid SCHEMBL4377519 | 0.98 | PARP1 (0.96) | PARP1CES2CES1PRSS1PRSS2 | |
| Hydrochloric Acid SCHEMBL407554 | 0.98 | PARP1 (0.96) | PARP1CES2CES1PRSS1PRSS2 | |
| Acetic Acid SCHEMBL4630445 | 0.94 | PARP1 (0.89) | PARP1CES2CES1PRSS1PRSS2 | |
| SCHEMBL7050338 | 0.93 | PARP1 (0.86) | PARP1CES2CES1PRSS1PRSS2 | |
| Terephthalamic Acid SCHEMBL7678892 | 0.90 | PARP1 (0.81) | PARP1CES2CES1PRSS1PRSS2 | |
| SCHEMBL1690557 | 0.89 | PARP1 (0.80) | PARP1CES2CES1PRSS1PRSS2 | |
| Trifluoroacetic Acid SCHEMBL28214522 | 0.88 | PARP1 (0.78) | PARP1CES2CES1PRSS1PRSS2 | |
| SCHEMBL13687397 | 0.88 | PARP10 (0.78) | PARP1CES2CES1PRSS1PRSS2 | |
| SCHEMBL28515342 | 0.87 | PARP1 (0.76) | PARP1CES2CES1PRSS1PRSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1879 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12575248-B2 | Zinc oxide nanomaterial and preparation method thereof and semiconductor device | TCL TECHNOLOGY GROUP CORPORATION (CN) | 2026-03-10 | — | — | US | claimed |
| EP-3623372-B1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | VALO HEALTH INC (US) | 2026-02-04 | — | — | EP | claimed |
| EP-4640686-A1 | DEGRADER FOR DEGRADING BRD PROTEIN AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | Innocure Therapeutics, Inc. (KR) | 2025-10-29 | — | — | EP | claimed |
| CN-119504475-A | N-alkylamine compound, preparation method and application | 南阳师范学院 | 2025-02-25 | — | — | CN | claimed |
| EP-4167307-B1 | ZINC OXIDE NANOMATERIAL AND PREPARATION METHOD THEREFOR, AND SEMICONDUCTOR DEVICE | TCL TECH GROUP CORP (CN) | 2025-02-05 | — | — | EP | claimed |
| CN-119371298-A | Method for efficiently synthesizing indenone compound | 南阳师范学院 | 2025-01-28 | — | — | CN | claimed |
| CN-115413278-B | Pyrimidine derivative and composition for preventing or treating neurodegenerative disease and cancer comprising same | 丸仁制药株式会社 | 2025-01-10 | — | — | CN | claimed |
| CN-118344283-A | Trifluoromethyl unit-containing substituted 2-piperidone compound and synthesis method thereof | 西南交通大学 | 2024-07-16 | — | — | CN | claimed |
| CN-116925562-B | Anthraquinone dye for color photoresist and application of anthraquinone dye in color photoresist and optical filter | 大连理工大学 | 2024-06-25 | — | — | CN | claimed |
| WO-2024112122-A1 | DEGRADER FOR DEGRADING BRD PROTEIN AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | 주식회사 이노큐어테라퓨틱스 | 2024-05-30 | — | — | WO | claimed |
| US-5985867-A | TREATING HIV INFECTION | DUPONT PHARMACEUTICALS COMPANY (US) | 1999-11-16 | — | — | US | claimed |
| US-5874444-A | CONTROLLING CELL AGING | GERON CORPORATION (US) | 1999-02-23 | — | — | US | claimed |
| WO-1998043969-A1 | INDAZOLES OF CYCLIC UREAS USEFUL AS HIV PROTEASE INHIBITORS | DUPONT PHARMACEUTICALS COMPANY (US) | 1998-10-08 | — | — | WO | claimed |
| WO-1998027975-A1 | POLY(ADP-RIBOSE) POLYMERASE INHIBITORS TO TREAT DISEASES ASSOCIATED WITH CELLULAR SENESCENCE | GERON CORPORATION (US) | 1998-07-02 | — | — | WO | claimed |
| EP-0775110-A1 | ARYLTHIO COMPOUNDS AS ANTIBACTERIAL AND ANTIVIRAL AGENTS | WARNER-LAMBERT COMPANY (US) | 1997-05-28 | — | — | EP | claimed |
| EP-0531370-B1 | INHIBITION OF VIRAL INFECTION | BRITISH TECH GROUP (GB) | 1996-09-18 | — | — | EP | claimed |
| WO-1996004242-A1 | ARYLTHIO COMPOUNDS AS ANTIBACTERIAL AND ANTIVIRAL AGENTS | WARNER-LAMBERT COMPANY (US) | 1996-02-15 | — | — | WO | claimed |
| EP-0531370-A1 | INHIBITION OF VIRAL INFECTION. | COLLINS MARY KATHARINE LEVINGE (GB) | 1993-03-17 | — | — | EP | claimed |
| WO-1991018591-A1 | INHIBITION OF VIRAL INFECTION | COLLINS MARY KATHARINE LEVINGE (GB) | 1991-12-12 | — | — | WO | claimed |
| US-3943152-A | Method for preparing azines | PRODUITS CHIMIQUES UGINE KUHLMANN (FR) | 1976-03-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12575248-B2 | Zinc oxide nanomaterial and preparation method thereof and semiconductor device | ZRANB2, ZKSCAN2, SLC39A3 | PARP1 3305/4885CES2 2168/4885CES1 3816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.